KRAS G12C mutation patient and physcian resources

Select disease state

Additional KRAS G12C support and resources for you and your practice

Help eligible patients get tested for KRAS G12C through Biomarker AssistTM

Biomarker AssistTM provides savings on tests that help identify the KRAS G12C mutation. Biomarker AssistTM is comprised of two programs:

  • Next-generation Sequence (NGS) Affordability Program: For eligible patients with commercial insurance, this program helps with reimbursement for NGS out-of-pocket costs. Patients can enroll in the program after a test is performed and the explanation of benefits is received
  • KRAS Single Gene Test (SGT) Program: This program is for eligible patients with all types of insurance plans, such as commercial, Medicare or Medicaid, or no insurance. The KRAS SGT Program allows a patient’s healthcare provider to submit a request form before a test is performed at no cost to the patient
Click through to learn about Biomarker AssistTM and for the full program summary and Terms and Conditions

Program is valid for testing performed through December 31, 2023.

A summary of the Biomarker AssistTM program
offerings for viewing on the go

Videos and podcasts

Mechanism of Disease (2:09 min)

An overview of the role of KRAS G12C in cancer

Leading the Way in NSCLC Biomarker Testing: An Educational Resource for Advanced Practice Providers (9:35 min)

An educational and interactive summary for advanced practice providers (APP) that offers insight into testing considerations, how to set expectations with patients, and receiving and reviewing test results in NSCLC

Featuring Andrew S. Guinigundo, an APP and Director of Precision Oncology at Cincinnati Cancer Advisors

Exploring Biomarker Testing in NSCLC: Actionable Biomarkers and Current Testing Guidelines (3:16 min)

An educational medical short for healthcare professionals about actionable biomarkers, biomarker testing, and current biomarker testing guidelines in advanced NSCLC

Featuring Dr. Ticiana Leal from the Winship Cancer Institute at Emory University School of Medicine

Examining Biomarker Testing Gaps in NSCLC (3:57 min)

An educational medical short for healthcare professionals about guideline recommendations, the benefits of broad biomarker testing, and current biomarker testing patterns and gaps in advanced NSCLC

Featuring Dr. Ticiana Leal from the Winship Cancer Institute at Emory University School of Medicine

Overcoming Biomarker Testing Barriers in NSCLC (5:04 min)

An educational medical short for healthcare professionals about biomarker testing methods, testing barriers, and considerations to overcome testing barriers in advanced NSCLC

Featuring Dr. Ticiana Leal from the Winship Cancer Institute at Emory University School of Medicine

Overcoming Testing Challenges in the Rapidly Evolving Landscape of NSCLC (10:20 min)

An overview of biomarker testing in NSCLC, including the most common barriers to testing and how to overcome them

Key Considerations in Biomarker Testing Journey in NSCLC (10:29 min)

A podcast featuring Dr. Pranil K. Chandra, who discusses the importance of testing, practice considerations for tissue preservation, and scenarios where liquid biopsy may be preferred

Considerations for Biomarker Testing in NSCLC (11:00 min)

A podcast featuring Dr. David R. Braxton, who discusses the importance of biomarker testing in clinical practice, improving turnaround time, and strategies for documentation

Downloadable resources for you and your practice

A resource that contains an overview of the biomarker testing landscape in NSCLC, including prevalence, guideline recommendations, and considerations for testing

A presentation providing disease state education on NSCLC biomarkers, identification, and testing

A brochure that outlines procedural elements of the testing process, such as verifying coverage, verifying benefits, and billing, as well as a sample billing and coding form

A 2-page document that summarizes how to test, record, and report on KRAS G12C as part of a biopsy, as well as a list of reference labs in the United States that test for KRAS G12C

A resource that outlines the coverage for
next-generation sequence testing for many commercial and Medicare insurance plans. The resource also includes a chart of steps for support coverage and prior authorization information

A resource developed by LUNGevity that can be used when discussing comprehensive biomarker testing with patients, featuring common questions patients may have and how to answer them

A resource developed by LUNGevity about comprehensive biomarker testing for your patients with lung cancer. It also includes helpful tips on when to use biomarker testing and some current barriers that you may face. Please see an additional reference to support the information in this factsheet: Billingy NE,
et al. Cancers (Basel). 2021;13(17):4282.

A longer-form guide providing a detailed overview of NSCLC biomarker testing. The overview incorporates data and guideline recommendations. These are enhanced further by perspectives and considerations on testing topics from expert faculty Maria E. Arcila, MD, Mark A. Socinski, MD, and Lauren Welch, MSN, NP-C, AOCNP

A single-page resource that lists and explains practice gaps in offering targeted therapy to patients with NSCLC. Please see an additional reference to support the information in this resource: Sadik H, et al. JCO Precision Oncology. 2022;6:e2200246.

Downloadable resources for your patients

A patient-focused disease state education resource that helps inform patients about biomarker testing, the KRAS G12C mutation, and other helpful guidance about these topics

A brief but detailed overview featuring questions and answers for patients about the purpose of biomarker testing, what testing for KRAS G12C is meant to accomplish, and how to get tested

A 2-page outline that offers step-by-step guidance for a patient's journey through metastatic NSCLC, including testing, biomarker analysis, and personalized therapy. The second page includes a list of questions for a patient to ask their healthcare providers during each step of the journey. This educational resource was developed in partnership with The Academy of Oncology Nurse and Patient Navigators®

An informative list of frequently asked questions that patients may have about biomarker testing developed by LUNGevity. The flashcard may help provide patients with a clearer understanding of what occurs with biomarker testing and may help better inform their treatment decisions

LUNGevity has developed a patient-directed overview about biomarker testing, what is involved, and what to expect with the testing process

A short discussion guide created by LUNGevity to help patients navigate conversations with their healthcare providers. The questions offer a linear path to help patients understand what tests they may need and what the results of those tests mean for them

A LUNGevity-created summary of patients' rights and considerations when undergoing comprehensive biomarker testing. This Bill of Rights helps set expectations for patients who may not be familiar with the process of biomarker testing

A resource offering support and guidance around a patient's lung cancer diagnosis. The resource looks at potential obstacles stemming from others' reactions to the new diagnosis, how to cope with or overcome those obstacles, and other organizations or outlets that offer support for patients

A conversation guide for patients to use when talking about their lung cancer diagnosis with their doctor. The guide provides a detailed list of potential care team members and their roles, topics to discuss with members of their care team, helpful questions to ask, and other organizational tools and skills for the patient to help themselves and to help others help them

*These third-party resources are for your information only. Amgen does not endorse and is not responsible for the content included in these resources.

KRAS, Kirsten rat sarcoma; NSCLC, non-small cell lung cancer.